Abstract
Remission and low disease activity (LDA) are the most important targets to achieve in systemic lupus erythematosus (SLE) management.1–4 Belimumab is the only biologic drug approved for SLE and whether...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
